113 related articles for article (PubMed ID: 17175181)
1. Apoptosis in raloxifene-treated postmenopausal women.
Biri A; Yurtcu E; Ciftci B; Korucuoğlu U; Ilhan MN; Ergun MA; Gursoy R; Biberoglu K
Cell Biol Int; 2007 Mar; 31(3):289-92. PubMed ID: 17175181
[TBL] [Abstract][Full Text] [Related]
2. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
3. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
4. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene.
Tommaselli GA; Di Carlo C; Di Spiezio Sardo A; Bifulco G; Cirillo D; Guida M; Capasso R; Nappi C
Menopause; 2006; 13(4):660-8. PubMed ID: 16837888
[TBL] [Abstract][Full Text] [Related]
5. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
6. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
Gol M; Baris N; Guneri S; Posaci C
Am J Obstet Gynecol; 2006 May; 194(5):1249-54. PubMed ID: 16647907
[TBL] [Abstract][Full Text] [Related]
7. [Raloxifene in postmenopausal women].
Trémollières F; Ribot C
Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
[TBL] [Abstract][Full Text] [Related]
8. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
Ozeren M; Karahan SC; Ozgur M; Eminagaoglu S; Unsal M; Baytan S; Bozkaya H
Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women.
Biri A; Korucuoglu U; Ilhan MN; Ciftci B; Bozkurt N; Guner H
Arch Gynecol Obstet; 2009 Apr; 279(4):505-9. PubMed ID: 18690468
[TBL] [Abstract][Full Text] [Related]
10. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
[TBL] [Abstract][Full Text] [Related]
11. Effects of raloxifene on mood, sleep, libido and cognitive function in postmenopausal healthy women: a pilot study.
Natale V; Albertazzi P; Missiroli N; Pedrini D; Salgarello M
Maturitas; 2004 May; 48(1):59-63. PubMed ID: 15223109
[TBL] [Abstract][Full Text] [Related]
12. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
13. The long-term effect of raloxifene on the genitourinary tract.
Sharma S; Albertazzi P; Bottazzi M
Climacteric; 2007 Jun; 10(3):244-8. PubMed ID: 17487651
[TBL] [Abstract][Full Text] [Related]
14. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
15. [Effects of raloxifene on bone biomarkers in postmenopausal women on maintenance haemodialysis].
Matsuo K; Fujinaga M; Tsuchiya K; Nakamoto M; Yasunaga C
Clin Calcium; 2005 Sep; 15 Suppl 1():92-6; discussion 96-7. PubMed ID: 16272639
[TBL] [Abstract][Full Text] [Related]
16. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
17. Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women.
van Essen HW; Holzmann PJ; Blankenstein MA; Lips P; Bravenboer N
Calcif Tissue Int; 2007 Sep; 81(3):183-90. PubMed ID: 17676256
[TBL] [Abstract][Full Text] [Related]
18. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
Urano T
Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
[TBL] [Abstract][Full Text] [Related]
19. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women.
Azevedo GD; Franco RF; Baggio MS; Maranhão TM; Ferriani RA; Silva de Sá MF
Climacteric; 2003 Jun; 6(2):140-5. PubMed ID: 12841884
[TBL] [Abstract][Full Text] [Related]
20. Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women.
Morgante G; Delia A; Musacchio MC; Severi FM; Petraglia F; De Leo V
Gynecol Endocrinol; 2006 Jul; 22(7):376-80. PubMed ID: 16864147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
